---
layout: use-case
title: "Autonomous Clinical Trial Patient Matching and Recruitment with Agentic AI"
uc_id: "UC-059"
category: "Industry-Specific"
category_dir: "industry-specific"
category_icon: "briefcase"
industry: "Pharmaceutical / Life Sciences"
complexity: "High"
status: "detailed"
summary: "Agentic AI system that autonomously orchestrates clinical trial patient matching and recruitment across protocol analysis, EHR scanning, patient identification, and enrollment monitoring."
slug: "uc-059-clinical-trial-patient-matching-recruitment-agentic-ai"
has_solution_design: true
has_implementation_guide: true
has_evaluation: true
has_references: true
permalink: /use-cases/uc-059-clinical-trial-patient-matching-recruitment-agentic-ai/
---

## Problem Statement

Clinical trial patient recruitment is the single largest bottleneck in drug development. Approximately 80% of clinical trials are delayed or closed because of enrollment failures. Patient recruitment accounts for 32-40% of total trial costs — roughly $1.89 billion annually in the US pharmaceutical sector alone. The average cost to recruit one patient is $6,500+, while replacing a patient who drops out costs $19,000+. Screen failures cost sponsors $1,200 each and occur at rates of 15-30% across therapeutic areas.

The manual process of matching patients in electronic health records (EHR) to complex, multi-criteria eligibility protocols is slow, error-prone, and unscalable. Each day a trial is delayed costs sponsors between $600,000 and $8 million in lost revenue from postponed product launch. The work requires site coordinators to manually review EHRs searching for patients meeting 30-50+ discrete eligibility requirements, often buried in unstructured clinical notes.

---

## Business Impact

| Dimension | Description |
|-----------|-------------|
| **Cost** | $6,500+ per enrolled patient; $1,200 per screen failure; recruitment = 32-40% of total trial budget ($1.89B/year in US). Average Phase III trial costs $11.5M in recruitment alone. |
| **Time** | 80% of trials delayed by enrollment; average enrollment period is 12-18 months for Phase III; each day of delay costs $600K-$8M in lost revenue. |
| **Error Rate** | 15-30% screen failure rate across therapeutic areas; manual chart review misses ~20% of eligible patients due to unstructured data buried in clinical notes. |
| **Scale** | ~440,000 active clinical trials globally; average Phase III requires 1,000-3,000 patients across 50-200 sites; each site coordinator manually reviews 50-100 charts per week. |
| **Risk** | Trials that fail to enroll on time face protocol amendments ($500K+ each), site closures, regulatory timeline slippage, and potential loss of patent exclusivity window. |

## Desired Outcome

An agentic AI system that autonomously orchestrates clinical trial patient matching and recruitment across the entire workflow — from protocol analysis through patient identification, site optimization, and enrollment monitoring. The system deploys specialized AI agents that: (1) parse and decompose complex eligibility criteria into machine-executable logic; (2) continuously scan structured and unstructured EHR data to identify candidate patients in near real-time; (3) score and rank candidates by match confidence and enrollment likelihood; (4) optimize site selection using predictive analytics; (5) monitor enrollment velocity and autonomously trigger corrective actions. Human clinical teams remain in the loop for final patient consent, clinical judgment on edge cases, and regulatory oversight.

### Success Criteria

| Metric | Target |
|--------|--------|
| Patient identification speed | From weeks to hours per cohort |
| Screen failure rate | Reduce from 15-30% to < 5% |
| Enrollment timeline | 25-50% reduction vs. historical baseline |
| Site activation time | 30-40% reduction through automated feasibility |
| Patient-trial match accuracy | > 95% concordance with manual expert review |
| Diversity enrollment | Meet FDA diversity action plan targets |
| Coordinator time on screening | Reduce by 60-80% (from 15-20 hrs/wk to 3-5 hrs/wk) |

## Stakeholders

| Role | Interest |
|------|----------|
| VP Clinical Operations (Sponsor) | Reduce enrollment timelines and cost per patient; accelerate time-to-market |
| Principal Investigators (Sites) | Reduce coordinator burden; improve screen success rate; increase enrollment credits |
| Site Study Coordinators | Automated patient identification to replace manual chart review |
| Chief Medical Officer (Sponsor) | Protocol feasibility validation; ensure patient safety in matching logic |
| Regulatory Affairs | Compliance with ICH-GCP, 21 CFR Part 11, FDA diversity guidance |
| Patients | Increased awareness of relevant trials; reduced screen failure burden |
| Data Privacy / IT Security | HIPAA-compliant EHR access; de-identification; audit trails |
| CRO Project Management | Real-time enrollment dashboards; predictive site performance |
| Health Equity / DEI Officers | Ensure diverse patient populations are identified and enrolled |

## Constraints

| Constraint | Detail |
|-----------|--------|
| **Data Privacy** | HIPAA (US), GDPR (EU) compliance for all patient data; EHR access requires BAA agreements with health systems; patient data de-identified or accessed under IRB-approved waivers; 21 CFR Part 11 for electronic records and signatures. |
| **Latency** | Patient matching near-real-time (within hours of new EHR data); site feasibility is batch (daily/weekly); enrollment monitoring is continuous with alerting thresholds. |
| **Budget** | AI platform costs must be offset by recruitment cost savings; typical ROI threshold: $2M+ savings on Phase III trial to justify platform licensing ($200K-$500K/year). |
| **Existing Systems** | Must integrate with major EHR systems (Epic, Cerner/Oracle Health, MEDITECH); must feed into CTMS (Medidata Rave, Oracle Siebel CTMS, Veeva Vault); HL7 FHIR APIs required. |
| **Compliance** | ICH-GCP (Good Clinical Practice) guidelines; FDA 21 CFR Parts 11 and 50; EU Clinical Trials Regulation (CTR) No 536/2014; FDA Diversity Action Plans for clinical trial enrollment (2024 guidance). |
| **Scale** | Must support concurrent matching across 50-200 trial sites, 10-50 active protocols simultaneously, and health system networks with millions of patient records. Peak load during large oncology or cardiovascular Phase III trials. |

## Scope Boundaries

### In Scope

- Automated parsing of trial protocols and decomposition of eligibility criteria into structured, executable rules
- NLP-powered scanning of structured and unstructured EHR data (clinical notes, labs, imaging reports, medication histories)
- Patient-trial matching with confidence scoring and explainable reasoning
- Predictive site selection and feasibility assessment using historical enrollment data
- Real-time enrollment monitoring with automated alerts and corrective action recommendations
- Integration with EHR systems (Epic, Cerner) via FHIR APIs and CTMS platforms (Medidata, Veeva)
- Diversity and inclusion analytics to support FDA diversity action plan compliance
- Audit trails and explainability for regulatory inspection readiness

### Out of Scope

- Electronic informed consent (eConsent) platforms and patient-facing consent workflows
- Clinical data management and EDC (electronic data capture) within the trial
- Adverse event detection and pharmacovigilance (covered by UC-050)
- Clinical documentation and medical coding (covered by UC-055)
- Drug discovery, target identification, and preclinical research
- Site payment and financial management
- Decentralized / virtual trial technology (wearables, remote monitoring devices)
